Oruka Therapeutics Statistics
Want to see ORKA full AI Analyst Report?
Oruka Therapeutics (ORKA) Stock Statistics & Valuation Metrics
Total Valuation
Oruka Therapeutics has a market cap or net worth of $7.27B. The enterprise value is $5.05B.
- Market Cap
- $7.27B
- Enterprise Value
- $5.05B
Share Statistics
Oruka Therapeutics has 67,822,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 67,822,360
- Owned by Insiders
- 7.49%
- Owned by Institutions
- 52.95%
Financial Efficiency
Oruka Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -25.76%.
- Return on Equity (ROE)
- -0.22
- Return on Assets (ROA)
- -0.22
- Return on Invested Capital (ROIC)
- -25.76%
- Return on Capital Employed (ROCE)
- -0.26
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.55M
- Employee Count
- 68
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Oruka Therapeutics is -43.80. Oruka Therapeutics’s PEG ratio is -1.79.
- PE Ratio
- -43.80
- PS Ratio
- 0.00
- PB Ratio
- 6.31
- Price to FCF
- -57.80
- Price to Operating Cash Flow
- -61.12
- PEG Ratio
- -1.79
Income Statement
In the last 12 months, Oruka Therapeutics had revenue of 0 and earned -105.43M in profits. Earnings per share was -2.31.
- Revenue
- 0
- Gross Profit
- -83.00K
- Operating Income
- -122.05M
- Pretax Income
- -105.43M
- Net Income
- -105.43M
- EBITDA
- -105.35M
- Earnings Per Share (EPS)
- -2.31
Cash Flow
In the last 12 months, operating cash flow was -123.64M and capital expenditures -219,000, giving a free cash flow of -123.86M billion.
- Operating Cash Flow
- -123.64M
- Free Cash Flow
- -123.86M
- Free Cash Flow per Share
- -1.73
Dividends & Yields
Oruka Therapeutics pays an annual dividend of $19.36, resulting in a dividend yield of ―
- Dividend Per Share
- $19.36
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.74%
- Earnings Yield
- -2.03%
Stock Price Statistics
- Beta
- 0.86
- 52-Week Price Change
- 270.99%
- 50-Day Moving Average
- 88.83
- 200-Day Moving Average
- 72.21
- Relative Strength Index (RSI)
- 64.08
- Average Volume (3m)
- 954.01K
Important Dates
Oruka Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- Aug 29, 2024
Financial Position
Oruka Therapeutics as a current ratio of 22.37, with Debt / Equity ratio of 0.41%
- Current Ratio
- 22.37
- Quick Ratio
- 22.37
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.43
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Oruka Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Oruka Therapeutics EV to EBITDA ratio is -39.96, with an EV/FCF ratio of -55.97.
- EV to Sales
- 0.00
- EV to EBITDA
- -39.96
- EV to Free Cash Flow
- -55.97
- EV to Operating Cash Flow
- -56.07
Balance Sheet
Oruka Therapeutics has $920.28M in cash and marketable securities with $2.93M in debt, giving a net cash position of $917.35M billion.
- Cash & Marketable Securities
- $920.28M
- Total Debt
- $2.93M
- Net Cash
- $917.35M
- Net Cash Per Share
- $13.53
- Tangible Book Value Per Share
- $16.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Oruka Therapeutics is $153.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $153.60
- Price Target Upside
- 46.30% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 12
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -2.35%
Scores
- Smart Score
- 9
- AI Score
- 68
